Ledipasvir/sofosbuvir - Gilead Sciences

Drug Profile

Ledipasvir/sofosbuvir - Gilead Sciences

Alternative Names: GS 5885/PSI 7977; GS-5885/GS-7977; GS-5885/sofosbuvir; GS-7977/GS-5885; Harvoni; LDV/SOF; PSI 7977/GS 5885; Sofosbuvir/GS-5885; Sofosbuvir/ledipasvir

Latest Information Update: 19 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Developer Gilead Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health (USA); The French National Agency for Research on AIDS and Viral Hepatitis
  • Class Antivirals; Azabicyclo compounds; Benzimidazoles; Carbamates; Fluorenes; Imidazoles; Phosphoric acid esters; Pyrimidine nucleotides; Small molecules; Spiro compounds
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C
  • Phase II Hepatitis B; Liver disorders

Most Recent Events

  • 24 Aug 2018 Gilead Sciences completes a phase II trial in Hepatitis C (In adolescents, In children) in United Kingdom, USA, New Zealand, Australia (PO) (NCT02249182)
  • 14 Aug 2018 Phase-II clinical trials in Hepatitis C (In children, Combination therapy) in USA (PO) before August 2018
  • 14 Aug 2018 Gilead Sciences completes a phase II trial in Hepatitis C (In children, Combination therapy, Monotherapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top